Insulet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. 

CEO
Ashley A. McEvoy
CEOAshley A. McEvoy
Employees
5,400
Employees5,400
Headquarters
Acton, Massachusetts
HeadquartersActon, Massachusetts
Founded
2000
Founded2000
Employees
5,400
Employees5,400

PODD Key Statistics

Market cap
10.41B
Market cap10.41B
Price-Earnings ratio
25.37
Price-Earnings ratio25.37
Dividend yield
—
Dividend yield—
Average volume
1.47M
Average volume1.47M
High today
$150.35
High today$150.35
Low today
$146.15
Low today$146.15
Open price
$148.09
Open price$148.09
Volume
950.79K
Volume950.79K
52 Week high
$354.88
52 Week high$354.88
52 Week low
$126.40
52 Week low$126.40

Stock Snapshot

As of today, Insulet(PODD) shares are valued at $150.03. The company's market cap stands at 10.41B, with a P/E ratio of 25.37.

During the trading session on 2026-11-12, Insulet(PODD) shares reached a daily high of $150.35 and a low of $146.15. At a current price of $150.03, the stock is +2.7% higher than the low and still -0.2% under the high.

Trading activity shows a volume of 950.79K, compared to an average daily volume of 1.47M.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $126.40.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $126.40.

PODD News

Simply Wall St 22h
Insulet Could Be 20% Undervalued As Guidance Rises And Buyback Begins

Insulet (PODD) just paired a strong third quarter earnings release with higher full year revenue guidance and a new US$1b share repurchase plan, giving investor...

Insulet Could Be 20% Undervalued As Guidance Rises And Buyback Begins
Zacks 1d
Is Insulet a Solid Growth Stock? 3 Reasons to Think "Yes"

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and delive...

Is Insulet a Solid Growth Stock? 3 Reasons to Think "Yes"
Simply Wall St 7d
Insulet Stock Has The Bull Case Changed After Earnings Beat

Insulet reported past third quarter 2026 revenue of US$842 million and net income of US$141.1 million, beating analyst expectations and lifting earnings per sha...

Insulet Stock Has The Bull Case Changed After Earnings Beat

Analyst ratings

55%

of 29 ratings
Buy
55.2%
Hold
44.8%
Sell
0%

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.